Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

immucillin H

Known as: 1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-iminoribitol, Forodesine, ImmH cpd 
A substance being studied in the treatment of some types of leukemia and lymphoma. It is a type of purine nucleoside phosphorylase (PNP) inhibitor.
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (1)

BCX1777

Broader (2)

Purine NucleosidesPyrimidinones
forodesine hydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Older and new purine nucleoside analogs for patients with acute leukemias.
Purine nucleoside analogs (PNAs) compose a class of cytotoxic drugs that have played an important role in the treatment of… Expand
Review
2012
Review
2012
Current and Emerging Treatment Strategies for Cutaneous T-cell Lymphoma
Cutaneous T-cell lymphomas (CTCLs) are a rare group of mature T-cell lymphomas presenting primarily in the skin. The most common… Expand
  • figure 1
  • table I
  • table II
Review
2009
Review
2009
How I treat mycosis fungoides and Sézary syndrome.
The most common subtypes of primary cutaneous T-cell lymphomas are mycosis fungoides (MF) and Sézary syndrome (SS). The majority… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Highly Cited
2009
Highly Cited
2009
Transition state analogues of 5′-methylthioadenosine nucleosidase disrupt quorum sensing
SUMMARY 5′-Methylthioadenosine nucleosidase (MTAN) is a bacterial enzyme involved in S-adenosylmethionine-related quorum sensing… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Highly Cited
2009
Highly Cited
2009
Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM.
Chronic lymphocytic leukemia (CLL) is an incurable disease derived from the monoclonal expansion of CD5(+) B lymphocytes. High… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Highly Cited
2005
Highly Cited
2005
A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).
The discovery of purine nucleoside phosphorylase (PNP) deficiency and T lymphocytopenia suggested that inhibition of this enzyme… Expand
  • table 1
  • table 2
  • figure 2
  • table 3
  • figure 3
2003
2003
Structural basis for inhibition of human PNP by immucillin-H.
Purine nucleoside phosphorylase (PNP) catalyzes the phosphorolysis of the N-ribosidic bonds of purine nucleosides and… Expand
Highly Cited
2002
Highly Cited
2002
Purine-less Death in Plasmodium falciparumInduced by Immucillin-H, a Transition State Analogue of Purine Nucleoside Phosphorylase*
Plasmodium falciparum is responsible for the majority of life-threatening cases of malaria. Plasmodia species cannot synthesize… Expand
Highly Cited
2001
Highly Cited
2001
Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)--a novel potent and orally active immunosuppressive agent.
Patients with purine nucleoside phosphorylase (PNP) deficiency present a selective T-cell immunodeficiency. Inhibitors of PNP are… Expand
Highly Cited
2001
Highly Cited
2001
Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes
Transition-state theory has led to the design of Immucillin-H (Imm-H), a picomolar inhibitor of purine nucleoside phosphorylase… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE